Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04811027
Title Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immutep S.A.S.

hypopharynx cancer

oral squamous cell carcinoma

head and neck squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma


Eftilagimod alpha + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA | ESP | BEL

No variant requirements are available.